Baxter Squibb CC-486 Maintenance Therapy Treats AML Patients In Phase 3 Key Trials Get Positive Results

today, The(http:// of Baxter's SquibbCompany announcedthat its CC-486, as a maintenance therapy, achieved a statistically significant improvement in total survival (OS) and non-recurrent survival (RFS) in the patient's total survival (OS) and non-relapse (RFS) in the(http:// of the 3st CriticalTrial Trial for the Treatment of Patients with Acute Myeloid Leukemia (AML)QUAZAR AML-001Based on the positive results of the QUAZAR AML-001 trial, Boxei Is it plans to submit cc-486'sNew Drug(http://Application (NDA) in the first half of 2020About CC-486
CC-486 is a DNA methyl transferase inhibitor (DNMT) that alters gene expression at epigenetic levels and inhibits the proliferation of cancer cellsIn addition to being used in clinical trials for AML patients, CC-486 is also treated in Phase 2 clinical trials for Patients with T-cell lymphoma, as well as in patients with bone marrow hyperplasia syndrome (MDS) in Phase 2 and Phase 3 trialsThe quaZAR AML-001study called QUAZAR AML-001 was a randomized, double-blind, 3-phase trial with placebo-controlled groupsPatients who participated in the trial had moderate/low risk AML and had achieved first complete remission (CR) or complete remission and incomplete blood cell count remission (CRi) after undergoing strong induced chemotherapy 　　The results showed that at a median follow-up time of 41.2 months, the OS improved significantly compared to the placebo, with the median OS in the CC-486 group at 24.7 months and the placebo group at 14.8 months, reaching the main endpoint of the trial 　　The median RFS in the treatment group was 10.2 months, compared to 4.8 months in the placebo group In addition, the health (http:// associated quality of life (HRQoL) scores of CC-486 patients during treatment were maintained at baseline, reaching a critical secondary endpoint of the trial